Does antagonizing glucagon action with mAb A improve cardiac function and alleviate adverse remodelling post-myocardial infarction?
Antagonizing glucagon action represents a novel pharmacological intervention to alleviate cardiac dysfunction and adverse remodelling post-myocardial infarction.
mAb A-mediated cardioprotection post-myocardial infarction is associated with improved insulin sensitivity and a selective enhancement of glucose oxidation via, at least in part, enhancing branched chain amino acids catabolism. Antagonizing glucagon action represents a novel and effective pharmacological intervention to alleviate cardiac dysfunction and adverse remodelling post-myocardial infarction.
Karwi et al. (Wed,) studied this question.